Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant MDR-TB: How Much Better Are They?

Bastard M, Guglielmetti L, Huerga H, Hayrapetyan A, Khachatryan N, Yegiazaryan L, Faqirzai J, Hovhannisyan L, Varaine F, Hewison C.

Am J Respir Crit Care Med. 2018 Jul 3. doi: 10.1164/rccm.201801-0019LE. [Epub ahead of print] No abstract available.

PMID:
29969054
2.

Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia.

Hewison C, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A, Avaliani Z, Kiria N, Yegiazaryan L, Chumburidze N, Kirakosyan O, Atshemyan H, Qayyum S, Lachenal N, Varaine F, Huerga H.

Int J Tuberc Lung Dis. 2018 Jul 1;22(7):766-772. doi: 10.5588/ijtld.17.0840.

PMID:
29914602
3.

Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study.

Bastard M, Sanchez-Padilla E, du Cros P, Khamraev AK, Parpieva N, Tillyashaykov M, Hayrapetyan A, Kimenye K, Khurkhumal S, Dlamini T, Perez SF, Telnov A, Hewison C, Varaine F, Bonnet M.

PLoS One. 2018 Mar 8;13(3):e0193491. doi: 10.1371/journal.pone.0193491. eCollection 2018.

4.

Tuberculosis, human rights and ethics.

Varaine F.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1071. doi: 10.5588/ijtld.17.0556. No abstract available.

PMID:
28911345
5.

Six-Month Response to Delamanid Treatment in MDR TB Patients.

Hewison C, Ferlazzo G, Avaliani Z, Hayrapetyan A, Jonckheere S, Khaidarkhanova Z, Mohr E, Sinha A, Skrahina A, Vambe D, Vasilyeva I, Lachenal N, Varaine F.

Emerg Infect Dis. 2017 Oct;23(10). doi: 10.3201/eid2310.170468. Epub 2017 Oct 17.

6.

Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.

Guglielmetti L, Varaine F, Huerga H, Bonnet M, Rich ML, Mitnick CD.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700598. doi: 10.1183/13993003.00598-2017. Print 2017 Jul. No abstract available.

7.

Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.

Varaine F, Guglielmetti L, Mitnick CD.

Am J Respir Crit Care Med. 2017 Dec 1;196(11):1490-1491. doi: 10.1164/rccm.201705-0988LE. No abstract available.

PMID:
28715258
8.

(Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis.

Milstein M, Brzezinski A, Varaine F, Mitnick CD.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):18-23. doi: 10.5588/ijtld.16.0039. Review.

PMID:
28240568
9.

Outcomes from the first multidrug-resistant tuberculosis programme in Kenya.

Huerga H, Bastard M, Kamene M, Wanjala S, Arnold A, Oucho N, Chikwanha I, Varaine F.

Int J Tuberc Lung Dis. 2017 Mar 1;21(3):314-319. doi: 10.5588/ijtld.16.0661.

PMID:
28225342
10.

Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.

Varaine F, Guglielmetti L, Huerga H, Bonnet M, Kiria N, Sitienei JK, Rich M, Mitnick CD.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):1028-1029. No abstract available.

PMID:
27739887
11.

Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.

Tadolini M, Garcia-Prats AJ, D'Ambrosio L, Hewison C, Centis R, Schaaf HS, Marais BJ, Ferreira H, Caminero JA, Jonckheere S, Sinha A, Herboczek K, Khaidarkhanova Z, Hayrapetyan A, Khachatryan N, Urtkmelidze Ia, Loreti C, Esposito S, Matteelli A, Furin J, Varaine F, Migliori GB.

Eur Respir J. 2016 Sep;48(3):938-43. doi: 10.1183/13993003.00705-2016. Epub 2016 Jun 23. No abstract available.

12.

Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected Patients in Resource-Constrained Settings.

Huerga H, Mueller Y, Ferlazzo G, Mpala Q, Bevilacqua P, Vasquez B, Noël Mekiedje C, Ouattara A, Mchunu G, Weyenga HO, Varaine F, Bonnet M.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):e89-95. doi: 10.1097/QAI.0000000000000895.

PMID:
26910386
13.

Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.

Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, Hayrapetyan A, Themba D, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F.

Int J Tuberc Lung Dis. 2016 Feb;20(2):177-86. doi: 10.5588/ijtld.15.0962.

PMID:
26792469
14.

Implementing the Xpert® MTB/RIF Diagnostic Test for Tuberculosis and Rifampicin Resistance: Outcomes and Lessons Learned in 18 Countries.

Ardizzoni E, Fajardo E, Saranchuk P, Casenghi M, Page AL, Varaine F, Kosack CS, Hepple P.

PLoS One. 2015 Dec 15;10(12):e0144656. doi: 10.1371/journal.pone.0144656. eCollection 2015.

15.

The thin-layer agar method for direct phenotypic detection of multi- and extensively drug-resistant tuberculosis.

Ardizzoni E, Mulders W, Kotrikadze T, Aspindzelashvili R, Goginashvili L, Pangtey H, Varaine F, Bastard M, Rigouts L, de Jong BC.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1547-52. doi: 10.5588/ijtld.15.0136.

PMID:
26614200
16.

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid.

Brigden G, Hewison C, Varaine F.

Infect Drug Resist. 2015 Oct 30;8:367-78. doi: 10.2147/IDR.S68351. eCollection 2015. Review.

17.

Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs.

Barrera L, Cooreman E, de Dieu Iragena J, Drobniewski F, Duda P, Havelkova M, Hoffner S, Kam KM, Kim SJ, Labelle S, Lambregts K, Leimane V, Nunn P, Ramsay A, Raviglione M, Rich M, Ridderhof J, Rodrigues F, Rüsch-Gerdes S, Salfinger M, Scholten J, Selvakumar N, Shinnick T, Shul'gina M, Šķenders G, Sloutsky A, Small P, Van Deun A, Varaine F, Yagui M, Vincent V, Weyer K, Wright A, Zignol M.

Geneva: World Health Organization; 2008.

18.

Routine use of Xpert® MTB/RIF in areas with different prevalences of HIV and drug-resistant tuberculosis.

Page AL, Ardizzoni E, Lassovsky M, Kirubi B, Bichkova D, Pedrotta A, Lastrucci C, de la Tour R, Bonnet M, Varaine F.

Int J Tuberc Lung Dis. 2015 Sep;19(9):1078-83, i-iii. doi: 10.5588/ijtld.14.0951.

PMID:
26260829
19.

Reply: How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?

Bastard M, Bonnet M, du Cros P, Khamraev AK, Hayrapetyan A, Kimenye K, Khurkhumal S, Dlamini T, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F.

Am J Respir Crit Care Med. 2015 Jul 1;192(1):117-8. doi: 10.1164/rccm.201504-0747LE. No abstract available.

PMID:
26131996
20.

Revised definitions of multidrug-resistant tuberculosis treatment outcomes: closer to the reality?

Bastard M, Bonnet M, du Cros P, Khamraev AK, Hayrapetyan A, Kimenye K, Khurkhumal S, Dlamini T, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):355-8. doi: 10.1164/rccm.201407-1302LE. No abstract available.

PMID:
25635495
21.

Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage.

Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E, Blum MG, Rüsch-Gerdes S, Mokrousov I, Aleksic E, Allix-Béguec C, Antierens A, Augustynowicz-Kopeć E, Ballif M, Barletta F, Beck HP, Barry CE 3rd, Bonnet M, Borroni E, Campos-Herrero I, Cirillo D, Cox H, Crowe S, Crudu V, Diel R, Drobniewski F, Fauville-Dufaux M, Gagneux S, Ghebremichael S, Hanekom M, Hoffner S, Jiao WW, Kalon S, Kohl TA, Kontsevaya I, Lillebæk T, Maeda S, Nikolayevskyy V, Rasmussen M, Rastogi N, Samper S, Sanchez-Padilla E, Savic B, Shamputa IC, Shen A, Sng LH, Stakenas P, Toit K, Varaine F, Vukovic D, Wahl C, Warren R, Supply P, Niemann S, Wirth T.

Nat Genet. 2015 Mar;47(3):242-9. doi: 10.1038/ng.3195. Epub 2015 Jan 19.

PMID:
25599400
22.

Effects of treatment interruption patterns on treatment success among patients with multidrug-resistant tuberculosis in Armenia and Abkhazia.

Bastard M, Sanchez-Padilla E, Hewison C, Hayrapetyan A, Khurkhumal S, Varaine F, Bonnet M.

J Infect Dis. 2015 May 15;211(10):1607-15. doi: 10.1093/infdis/jiu551. Epub 2014 Oct 13.

PMID:
25312040
23.

Decontamination methods for samples preserved in cetylpyridinium chloride and cultured on thin-layer agar.

Ardizzoni E, Mulders W, Sanchez-Padilla E, Varaine F, de Jong BC, Rigouts L.

Int J Tuberc Lung Dis. 2014 Aug;18(8):972-7. doi: 10.5588/ijtld.13.0887.

PMID:
25199014
24.

Is introducing rapid culture into the diagnostic algorithm of smear-negative tuberculosis cost-effective?

Yakhelef N, Audibert M, Varaine F, Chakaya J, Sitienei J, Huerga H, Bonnet M.

Int J Tuberc Lung Dis. 2014 May;18(5):541-6. doi: 10.5588/ijtld.13.0630.

PMID:
24903790
25.

Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study.

Sanchez-Padilla E, Marquer C, Kalon S, Qayyum S, Hayrapetyan A, Varaine F, Bastard M, Bonnet M.

Int J Tuberc Lung Dis. 2014 Feb;18(2):160-7. doi: 10.5588/ijtld.13.0369.

PMID:
24429307
26.

Principles for designing future regimens for multidrug-resistant tuberculosis.

Brigden G, Nyang'wa BT, du Cros P, Varaine F, Hughes J, Rich M, Horsburgh CR Jr, Mitnick CD, Nuermberger E, McIlleron H, Phillips PP, Balasegaram M.

Bull World Health Organ. 2014 Jan 1;92(1):68-74. doi: 10.2471/BLT.13.122028. Epub 2013 Oct 25.

27.

Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients.

Merker M, Kohl TA, Roetzer A, Truebe L, Richter E, Rüsch-Gerdes S, Fattorini L, Oggioni MR, Cox H, Varaine F, Niemann S.

PLoS One. 2013 Dec 6;8(12):e82551. doi: 10.1371/journal.pone.0082551. eCollection 2013.

28.

Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions.

Sanchez-Padilla E, Ardizzoni E, Sauvageot D, Ahoua L, Martin A, Varaine F, Adatu-Engwau F, Akeche G, Salaniponi F, Bonnet M.

Int J Tuberc Lung Dis. 2013 Aug;17(8):1036-42. doi: 10.5588/ijtld.12.0842.

PMID:
23827027
29.

Performance of the 2007 WHO algorithm to diagnose smear-negative pulmonary tuberculosis in a HIV prevalent setting.

Huerga H, Varaine F, Okwaro E, Bastard M, Ardizzoni E, Sitienei J, Chakaya J, Bonnet M.

PLoS One. 2012;7(12):e51336. doi: 10.1371/journal.pone.0051336. Epub 2012 Dec 19.

30.

Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis.

Horsburgh CR Jr, Haxaire-Theeuwes M, Lienhardt C, Wingfield C, McNeeley D, Pyne-Mercier L, Keshavjee S, Varaine F; Research Excellence to Stop TB Resistance (RESIST-TB); Critical Path to TB Drug Regimens' Access and Appropriate Use Workgroup.

Int J Tuberc Lung Dis. 2013 Feb;17(2):146-52. doi: 10.5588/ijtld.12.0017. Epub 2012 Dec 4. Review.

PMID:
23211610
31.

Adherence to self-administered tuberculosis treatment in a high HIV-prevalence setting: a cross-sectional survey in Homa Bay, Kenya.

Nackers F, Huerga H, Espié E, Aloo AO, Bastard M, Etard JF, Sitienei J, Varaine F, Chakaya J, Bonnet M.

PLoS One. 2012;7(3):e32140. doi: 10.1371/journal.pone.0032140. Epub 2012 Mar 12.

32.

Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection.

Bonnet M, Pardini M, Meacci F, Orrù G, Yesilkaya H, Jarosz T, Andrew PW, Barer M, Checchi F, Rinder H, Orefici G, Rüsch-Gerdes S, Fattorini L, Oggioni MR, Melzer J, Niemann S, Varaine F.

PLoS One. 2011;6(8):e23081. doi: 10.1371/journal.pone.0023081. Epub 2011 Aug 23.

33.

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M.

Eur Respir J. 2011 Sep;38(3):516-28. doi: 10.1183/09031936.00073611. Epub 2011 Aug 4.

34.

Evaluation of combined LED-fluorescence microscopy and bleach sedimentation for diagnosis of tuberculosis at peripheral health service level.

Bonnet M, Gagnidze L, Guerin PJ, Bonte L, Ramsay A, Githui W, Varaine F.

PLoS One. 2011;6(5):e20175. doi: 10.1371/journal.pone.0020175. Epub 2011 May 31.

35.

Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs.

Nicholas S, Sabapathy K, Ferreyra C, Varaine F, Pujades-Rodríguez M; AIDS Working Group of Médecins Sans Frontières.

J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):311-8. doi: 10.1097/QAI.0b013e318218a713.

PMID:
21423023
36.

Performance of LED-based fluorescence microscopy to diagnose tuberculosis in a peripheral health centre in Nairobi.

Bonnet M, Gagnidze L, Githui W, Guérin PJ, Bonte L, Varaine F, Ramsay A.

PLoS One. 2011 Feb 18;6(2):e17214. doi: 10.1371/journal.pone.0017214.

37.

Impact of introducing human immunodeficiency virus testing, treatment and care in a tuberculosis clinic in rural Kenya.

Huerga H, Spillane H, Guerrero W, Odongo A, Varaine F.

Int J Tuberc Lung Dis. 2010 May;14(5):611-5.

PMID:
20392355
38.

Added value of bleach sedimentation microscopy for diagnosis of tuberculosis: a cost-effectiveness study.

Bonnet M, Tajahmady A, Hepple P, Ramsay A, Githui W, Gagdnidze L, Guérin PJ, Varaine F.

Int J Tuberc Lung Dis. 2010 May;14(5):571-7.

PMID:
20392349
39.

Thin-layer agar for detection of resistance to rifampicin, ofloxacin and kanamycin in Mycobacterium tuberculosis isolates.

Martin A, Paasch F, Von Groll A, Fissette K, Almeida P, Varaine F, Portaels F, Palomino JC.

Int J Tuberc Lung Dis. 2009 Oct;13(10):1301-4.

PMID:
19793437
40.

Evaluation of FASTPlaqueTB to diagnose smear-negative tuberculosis in a peripheral clinic in Kenya.

Bonnet M, Gagnidze L, Varaine F, Ramsay A, Githui W, Guerin PJ.

Int J Tuberc Lung Dis. 2009 Sep;13(9):1112-8.

PMID:
19723400
41.

Characteristics of drug-resistant tuberculosis in Abkhazia (Georgia), a high-prevalence area in Eastern Europe.

Pardini M, Niemann S, Varaine F, Iona E, Meacci F, Orrù G, Yesilkaya H, Jarosz T, Andrew P, Barer M, Checchi F, Rinder H, Orefici G, Rüsch-Gerdes S, Fattorini L, Oggioni MR, Bonnet M.

Tuberculosis (Edinb). 2009 Jul;89(4):317-24. doi: 10.1016/j.tube.2009.04.002. Epub 2009 Jun 17.

PMID:
19539531
42.

Implementation of the thin layer agar method for diagnosis of smear-negative pulmonary tuberculosis in a setting with a high prevalence of human immunodeficiency virus infection in Homa Bay, Kenya.

Martin A, Munga Waweru P, Babu Okatch F, Amondi Ouma N, Bonte L, Varaine F, Portaels F.

J Clin Microbiol. 2009 Aug;47(8):2632-4. doi: 10.1128/JCM.00264-09. Epub 2009 Jun 3.

43.

Thin layer agar compared to BACTEC MGIT 960 for early detection of Mycobacterium tuberculosis.

Martin A, Fissette K, Varaine F, Portaels F, Palomino JC.

J Microbiol Methods. 2009 Jul;78(1):107-8. doi: 10.1016/j.mimet.2009.05.001. Epub 2009 May 7.

PMID:
19427881
44.

Sputum, sex and scanty smears: new case definition may reduce sex disparities in smear-positive tuberculosis.

Ramsay A, Bonnet M, Gagnidze L, Githui W, Varaine F, Guérin PJ.

Int J Tuberc Lung Dis. 2009 May;13(5):613-9.

PMID:
19383195
45.

Rapid detection of Mycobacterium tuberculosis resistance to second-line drugs by use of the manual mycobacterium growth indicator tube system.

Martin A, von Groll A, Fissette K, Palomino JC, Varaine F, Portaels F.

J Clin Microbiol. 2008 Dec;46(12):3952-6. doi: 10.1128/JCM.01171-08. Epub 2008 Oct 22.

46.

Bleach sedimentation: an opportunity to optimize smear microscopy for tuberculosis diagnosis in settings of high prevalence of HIV.

Bonnet M, Ramsay A, Githui W, Gagnidze L, Varaine F, Guerin PJ.

Clin Infect Dis. 2008 Jun 1;46(11):1710-6. doi: 10.1086/587891.

PMID:
18444789
47.

Reducing the number of sputum samples examined and thresholds for positivity: an opportunity to optimise smear microscopy.

Bonnet M, Ramsay A, Gagnidze L, Githui W, Guerin PJ, Varaine F.

Int J Tuberc Lung Dis. 2007 Sep;11(9):953-8.

PMID:
17705971
48.

Pyrazinamide resistance in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Abkhazia.

Pardini M, Varaine F, Hewison C, Iona E, Pataracchia M, Orefici G, Fattorini L.

J Chemother. 2007 Feb;19(1):106-7. No abstract available.

PMID:
17309862
49.

Usefulness of the BACTEC MGIT 960 system for isolation of mycobacterium tuberculosis from sputa subjected to long-term storage.

Pardini M, Varaine F, Bonnet M, Orefici G, Oggioni MR; LONG-DRUG Study Group, Fattorini L.

J Clin Microbiol. 2007 Feb;45(2):575-6. Epub 2006 Nov 22.

50.

Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden.

Bonnet MM, Pinoges LL, Varaine FF, Oberhauser BB, O'Brien DD, Kebede YY, Hewison CC, Zachariah RR, Ferradini LL.

AIDS. 2006 Jun 12;20(9):1275-9.

PMID:
16816556

Supplemental Content

Loading ...
Support Center